Andrew P. Catchpole, PhD

hVivo Services Ltd.
London, England, United Kingdom

Disclosure information not submitted.

Presentation(s):

• 235 - EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge

  Monday, October 20, 2025
  4:15 PM - 4:27 PM US ET